

78. (New) A method of inhibiting an indication associated with a chemokine-induced activity, comprising: administering to a mammal afflicted with the indication an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74.

79. (New) A method of inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal afflicted with the indication an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74.

80. (New) A method of inhibiting chemokine-induced activity of hematopoietic cells at a preselected physiological site, comprising: administering to a mammal a dosage form comprising an effective amount of a peptide comprising no more than 30 amino acid residues, which peptide comprises SEQ ID NO:1, SEQ ID NO:7, SEQ ID NO:38, SEQ ID NO:40, SEQ ID NO:41, SEQ ID NO:42, SEQ ID NO:43, SEQ ID NO:44, SEQ ID NO:65, SEQ ID NO:66, SEQ ID NO:67, SEQ ID NO:68, SEQ ID NO:72, SEQ ID NO:73, or SEQ ID NO:74, wherein the dosage form is linked to a site targeting moiety.

81. (New) A method of inhibiting an indication associated with a chemokine-induced activity, comprising: administering to a mammal afflicted with the indication an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.

82. (New) A method of inhibiting an indication associated with hematopoietic cell recruitment, comprising: administering to a mammal afflicted with the indication an effective amount of CRD-Cys-Leu-Asp-Pro-Lys-Gln-Lys-Trp-Ile-Gln-Cys.